Clinics Say State’s New Medicaid Drug Program Will Pressure Them to Reduce Providers

SACRAMENTO — California’s sweeping new program to purchase pharmaceuticals for its practically 14 million Medicaid sufferers has alarmed well being clinics that say they’ll lose cash and have to chop companies.

Gov. Gavin Newsom acknowledged Monday that some clinics, which serve the poorest Californians, would lose funding, and he included $105 million for them within the 2022-23 proposed state price range he unveiled within the state capital. 

However the allocation falls far in need of what clinic officers say they should hold essential well being care companies funded in a few of California’s neediest areas. California’s federally certified well being facilities, which function greater than 1,000 clinics throughout the state, have filed a lawsuit in federal court docket to exempt them from this system, however a decide on Monday denied their request for a short lived reprieve whereas the lawsuit proceeds.

“Persons are going to be laid off; companies are going to be minimize,” mentioned Anthony White, president of the Group Well being Middle Alliance for Affected person Entry, a statewide group of federally certified well being facilities. “It’s going to lower entry for our sufferers.”

The drug program, generally known as Medi-Cal Rx, debuted Jan. 1 and is one in all Newsom’s key well being care initiatives. It takes the duty for prescription drug protection within the state’s Medicaid program away from managed-care plans and places it into the arms of a state contractor.

On his first day in workplace in 2019, Newsom promised the overhaul would ship higher well being look after sufferers and generate “substantial annual financial savings” as a result of the state would negotiate decrease costs as one of many largest drug purchasers within the nation. 

The Newsom administration anticipates the state will save $414 million within the 2022-23 price range 12 months and practically two occasions that quantity within the subsequent one, mentioned Keely Martin Bosler, director of the California Division of Finance. 

California’s well being clinics, nevertheless, might lose as much as $200 million a 12 months in drug reimbursements, White estimated, cash they’ve been utilizing to look after sufferers with bronchial asthma, HIV and different continual well being issues. The reimbursement cash is a key income stream for clinics, however they rely totally on federal grants for his or her funding, along with some affected person income and personal donations.

At concern is cash the clinics have acquired by means of a federal prescription drug financial savings program generally known as “340B.” The 340B program requires drug producers taking part in Medicaid to supply deep reductions to sure suppliers that look after underserved and uninsured individuals, together with well being clinics. The well being facilities, in flip, should use that cash to broaden well being care companies. 

Starting Jan. 1, California began shopping for pharmaceuticals for all its low-income and disabled residents enrolled in Medi-Cal, the nation’s largest Medicaid program. As a result of the state expects to get greater reductions on medication than the roughly two dozen Medi-Cal managed-care insurance policy did, clinics anticipate to obtain much less 340B cash. 

The $105 million Newsom earmarked for well being clinics in his price range proposal to offset their losses was not supposed to totally exchange them, mentioned Michelle Baass, director of the state Division of Well being Care Providers, which administers Medi-Cal, in the state’s Jan. 5 response to the clinics’ lawsuit.

“Plaintiffs don’t have any entitlement to continued income from promoting marked up 340B medication,” she wrote.

The funding Newsom proposed shouldn’t be assured. Certainly, it’s now topic to the annual price range negotiation course of. The legislature has till June 15 to barter with Newsom and undertake a deal. The 2022-23 state price range takes impact July 1. 

Mark Ghaly, secretary of the state’s Well being and Human Providers Company, mentioned the administration has been working with clinics and is open to additional discussions.

“We’re all the time completely happy to sit down down and attempt to perceive what the circumstances are right now,” Ghaly mentioned. 

California Healthline’s Angela Hart contributed to this report.

This story was produced by KHN, which publishes California Healthline, an editorially impartial service of the California Well being Care Basis.

Associated Matters

Contact Us

Submit a Story Tip


Supply By https://khn.org/information/article/clinics-lawsuit-prescription-drugs-medicaid/